The treatment of branch retinal vein occlusion with bevacizumab

Current Opinion in Ophthalmology

Volumn 19, Issue 3, 2008, Pages 234-238

  Badalà, Federico ^a  

^a Microchirurgia Oculare del Mediterraneo and Associati (MOMA)   (Italy)

Author keywords

Avastin; Bevacizumab; Branch retinal vein occlusion; Macular edema

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; POSURDEX; TISSUE PLASMINOGEN ACTIVATOR; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ARGON PLASMA COAGULATION; BRANCH RETINAL VEIN OCCLUSION; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; RETINA MACULA EDEMA; REVIEW; TREATMENT OUTCOME; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; HUMANS; INJECTIONS; RETINAL VEIN OCCLUSION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 42149139068     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e3282fb7fb0     Document Type: Review

References (28)

1. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984; 98:271-282. This paper establishes macular grid laser treatment as the standard of care for macular edema secondary to BRVO.
2. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 1996; 114:1243-1247.
3. Greer DV, Constable IJ, Cooper RL. Macular oedema and retinal branch vein occlusion. Aust J Ophthalmol 1980; 8:207-209.
4. Battaglia Parodi M, Saviano S, Ravalico G. Grid laser treatment in macular branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 1999; 237:1024-1027.
5. Battaglia Parodi M, Saviano S, Bergamini L, Ravalico G. Grid laser treatment of macular edema in macular branch retinal vein occlusion. Doc Ophthalmol 1999; 97 (3-4):427-431.
6. The Branch Vein Occlusion Study Group. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion: a randomized clinical trial. Arch Ophthalmol 1986; 104:34-41.
7. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331:1480-1487.
8. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005; 36:336-339.
9. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006; 26:279-284.
10. Rabena MD, Pieramici DJ, Castellarin AA, et al. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 2007; 27:419-425. This is a retrospective review that well elucidates most of the characteristics features of bevacizumab treatment after BRVO. Twenty-seven cases responded to bevacizumab 1.25mg. More than 80% of patients failed prior laser treatment or intravitreal steroids.
11. Stahl A, Agostini H, Hansen LL, Feltgen N. Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 2007; 245:1429-1436. In this prospective case series using 2.5mg of intravitreal bevacizumab there was a similar response as to intravitreal bevacizumab 1.25 mg.
12. Pai SA, Shetty R, Vijayan PB, et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 2007; 143:601-606.
13. Schaal KB, Höh AE, Scheuerle A, et al. Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe 2007; 104:285-289.
14. Matsumoto Y, Freund KB, Peiretti E, et al. Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina 2007; 27:426-431. This article presents three cases that manifested the only significant complication reported after the use of intravitreal bevacizumab for vein occlusion.
15. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007; 27:141-149. This prospective case series used 2.0mg of intravitreal bevacizumab mostly in patients with central retinal vein occlusion.
16. Schultz A, Lavie L, Hochberg I, et al. Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. Circulation 1999; 100:547-552.
17. Lin TH, Yen HW, Voon WC, et al. Vascular endothelial growth factor in coronary sinus: evidence for its association with coronary collaterals. Scand Cardiovasc J 2005; 39:353-357.
18. Chen SD, Sundaram V, Lochhead J, Patel CK. Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2006; 141:876-883.
19. Cekic O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina 2005; 25:851-855.
20. Cekic O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion. Retina 2005; 25:846-850.
21. Jonas JB, Akkoyun I, Kamppeter B, et al. Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye 2005; 19:65-71.
22. Cekic O, Chang S, Tseng JJ, et al. Cataract progression after intravitreal triamcinolone injection. Am J Ophthalmol 2005; 139:993-998.
23. Jonas J, Heatley G, Spaide R, Varma R. Intravitreal triamcinolone acetonide and secondary ocular hypertension. J Glaucoma 2005; 14:168-171.
24. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004; 138:740-743.
25. Kaushik S, Gupta V, Gupta A, et al. Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion. Am J Ophthalmol 2004; 137:758-760.
26. Murakami T, Takagi H, Kita M, et al. Intravitreal tissue plasminogen activator to treat macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2006; 142:318-320.
27. Chen SN, Yang TC, Ho CL, et al. Retinal toxicity of intravitreal tissue plasminogen activator: case report and literature review. Ophthalmology 2003; 110:704-708.
28. McIntosh RL, Mohamed Q, Saw SM, Wong TY. Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007; 114:835-854.